新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Retrophin计划进行总额达4000万美元IPO

Retrophin计划进行总额达4000万美元IPO

来源:生物谷 2013-12-20 22:27

2013年12月20日讯 /生物谷BIOON/ --2013年12月对Retrophin来说是一个忙碌的月份,公司计划在今年登陆纳斯达克进行IPO,总募资金额达到4000万美元。Retrophin公司刚刚从诺华公司以500万美元的价格获得了用于治疗精神分裂症和孤独症的催产素吸入式喷雾项目。公司目前还有一项处于二期研究的局灶性节段性肾小球硬化症项目以及处于早期研究阶段的肾病综合症、婴儿痉挛症和神经退行性疾病等项目。(生物谷Bioon.com)

详细英文报道:

It's been a busy month for Retrophin ($RTRX), and CEO Martin Shkreli is capping it off with an IPO filing, looking to take his company from over-the-counter trading to the Nasdaq and pick up $40 million in the process. The biotech recently traded $5 million for Novartis' ($NVS) oxytocin nasal spray with hopes of developing the long-shelved drug into a treatment for schizophrenia and autism, a move that grabbed headlines--though many of them boiled down to "Is Retrophin for real?" The company's pipeline also includes a Phase II treatment for focal segmental glomerulosclerosis and early stage drugs targeting nephrotic syndrome, infantile spasms and neurodegeneration.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库